Wedbush Has Positive Estimate for Biogen Q4 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Analysts at Wedbush lifted their Q4 2025 EPS estimates for Biogen in a research note issued to investors on Friday, May 2nd. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $3.95 for the quarter, up from their previous forecast of $3.87. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q1 2026 earnings at $4.06 EPS, Q2 2026 earnings at $4.06 EPS, Q3 2026 earnings at $3.94 EPS, Q4 2026 earnings at $3.73 EPS, FY2027 earnings at $16.97 EPS, FY2028 earnings at $20.23 EPS and FY2029 earnings at $20.95 EPS.

A number of other analysts have also commented on BIIB. Morgan Stanley reduced their price target on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Robert W. Baird cut their target price on shares of Biogen from $300.00 to $255.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group lowered their price target on Biogen from $219.00 to $197.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Bank Of America (Bofa) cut their price objective on Biogen from $178.00 to $163.00 and set a "neutral" rating for the company in a report on Tuesday, February 11th. Finally, Scotiabank reduced their price objective on Biogen from $244.00 to $224.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 13th. Twenty investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $191.30.

Biogen Stock Performance

NASDAQ:BIIB traded up $0.43 during mid-day trading on Monday, reaching $118.82. The company's stock had a trading volume of 202,590 shares, compared to its average volume of 1,619,011. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The stock has a market cap of $17.41 billion, a P/E ratio of 10.62, a PEG ratio of 1.51 and a beta of 0.12. The firm's fifty day moving average price is $128.82 and its two-hundred day moving average price is $145.11. Biogen has a 12-month low of $110.04 and a 12-month high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The business had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a return on equity of 14.98% and a net margin of 16.87%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.67 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Earned Wealth Advisors LLC purchased a new stake in shares of Biogen in the first quarter worth about $205,000. Blair William & Co. IL raised its holdings in shares of Biogen by 1.8% during the 1st quarter. Blair William & Co. IL now owns 13,283 shares of the biotechnology company's stock worth $1,818,000 after acquiring an additional 234 shares in the last quarter. R Squared Ltd boosted its position in shares of Biogen by 249.4% during the 1st quarter. R Squared Ltd now owns 2,760 shares of the biotechnology company's stock valued at $378,000 after acquiring an additional 1,970 shares during the last quarter. Banco Santander S.A. grew its holdings in shares of Biogen by 15.0% in the first quarter. Banco Santander S.A. now owns 54,991 shares of the biotechnology company's stock valued at $7,525,000 after purchasing an additional 7,182 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its position in Biogen by 20.4% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 53,280 shares of the biotechnology company's stock worth $7,329,000 after purchasing an additional 9,014 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares of the company's stock, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.